Fractyl Health (NASDAQ:GUTS) Issues Quarterly Earnings Results

Fractyl Health (NASDAQ:GUTS) announced its quarterly earnings data on Tuesday. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02, Zacks reports. The firm had revenue of $0.01 million during the quarter.

Fractyl Health Stock Up 4.2 %

Shares of NASDAQ GUTS opened at $2.47 on Thursday. The business has a 50-day moving average of $2.63 and a two-hundred day moving average of $4.05. The company has a market capitalization of $118.38 million and a price-to-earnings ratio of -0.19. Fractyl Health has a 1 year low of $1.74 and a 1 year high of $14.50. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.46 and a quick ratio of 7.46.

Insider Activity

In other news, insider Jay David Caplan sold 65,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $2.90, for a total value of $188,500.00. Following the completion of the transaction, the insider now owns 30,484 shares in the company, valued at approximately $88,403.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Harith Rajagopalan sold 96,517 shares of Fractyl Health stock in a transaction on Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $238,396.99. Following the transaction, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at $1,213,582.63. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jay David Caplan sold 65,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $2.90, for a total transaction of $188,500.00. Following the sale, the insider now owns 30,484 shares of the company’s stock, valued at approximately $88,403.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 225,714 shares of company stock worth $585,464.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.